Teva Launched LAI-CARE

The LAI‑CARE educational platform is designed to facilitate informed, collaborative conversations about long-acting injectable antipsychotics (LAIs) for schizophrenia. Aimed at healthcare professionals, people living with schizophrenia, and care partners, this resource supports person-centered, adherence-focused discussions around treatment planning.

Of particular note for mental health advocates and research professionals is the LAI-CARE for Caregivers section, which offers practical, stigma-sensitive resources to help families navigate one of the most persistent challenges in treatment: adherence.

This section answers key questions like “Why is adherence so important?” and “How can I help my loved one stay on track?”—equipping caregivers with tips on building trust, identifying early warning signs, and providing support without diminishing the individual’s autonomy.

The platform includes downloadable conversation guides, educational tools, and plain-language explanations that help demystify the role of LAIs in relapse prevention and long-term stability. For clinical researchers, this resource may also support improved patient engagement and retention strategies—particularly in studies involving LAIs.

Why This Matters to the STARR Community

The STARR Community is committed to supporting not only research participants, but also their families and support networks. LAI-CARE is a powerful tool that sites can share with caregivers of patient study volunteers to improve understanding, reduce stigma, and foster shared decision-making beyond the research setting. As we work together to promote trust in clinical research and support continuity of care, tools like LAI-CARE help bridge the gap between research participation and real-world mental health outcomes. We encourage all STARR Site teams and advocates to explore the platform and consider integrating it into participant education and caregiver outreach.